Metaplastic breast carcinoma: a rare breast cancer with distinct biology and therapeutic challenges - Nature
This story deserves to be shared
Send it to someone who'd care, or post it on your networks.
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
AbstractMetaplastic breast carcinoma (MpBC) is a rare, histologically heterogeneous breast cancer typically treated with regimens developed for triple-negative breast cancer (TNBC), despite distinct biology and insufficient response to standard therapy. MpBC is defined by differentiation of malignant epithelial cells toward non-glandular lineages, reflecting a plasticity that complicates biomarker interpretation and distinguishes it from non-metaplastic TNBC. In this review, we cover MpBC histopathology, biology, and therapeutic development, calling for dedicated clinical investigation that recognizes MpBC as a biologically distinct entity.
This article is an excerpt. To read the full content, visit the original source. Nature
Related articles
Immunotherapy-Based Downstaging Linked to Improved Outcomes After Liver Transplantation in Hepatocellular Carcinoma - The ASCO Post
An immune checkpoint inhibitor–based multimodal downstaging strategy before liver transplantation was associated with improved posttransplant survival and a lower risk of recurrence among patients with hepatocellular carcinoma initially beyond the Milan criteria (single lesion not larger than 5 cm or two or three lesions not larger than 3 cm each), based on findings from a Chinese study published in JAMA Oncology. However, according to Ong et al, the strategy was also associated with a higher rate of acute rejection within 90 days posttransplantation. “By characterizing this post–liver transplantation benefit-risk profile, this multicenter matched cohort study may inform future prospective studies of immune checkpoint inhibitor–based pretransplant strategies in liver transplantation candidates and help clinical decision-making,” the investigators wrote.
Retifanlimab Versus Avelumab for Metastatic Merkel Cell Carcinoma: Comparative Analysis Insights - DocWireNews
Results from a recent matching-adjusted indirect comparison (MAIC) analysis indicated clinical favorability of retifanlimab versus avelumab for the treatment of metastatic Merkel cell carcinoma (MCC), which investigators described as “a rare and aggressive skin cancer with poor prognosis and low survival rate. A team of researchers from Italy conducted the study and published their findings in Advances in Therapy. Both retifanlimab and avelumab are classified as monoclonal immune checkpoint inhibitor (ICI) antibodies, and investigators highlighted that both medications are approved for the treatment of metastatic or locally advanced recurrent MCC. They explained that the goal of their research was to assess clinical outcomes of both ICIs via a MAIC analysis of data from the phase 2 POD1UM-201 trial and part B of the phase 2 JAVELIN Merkel 200 trial. Patient data from each trial were used in the analysis, with data from POD1UM-201 informing the retifanlimab group and aggregate data from JAVELIN Merkel 200 informing the avelumab treatment group. Investigators also underscored that the data cutoff of POD1UM-201 was July 2024.
0 comments
No comments yet. Be the first to share your thoughts!